Daniele Regge

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 1K citations · Full text

Medicine, Oncology, Pharmacology +14

Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study

Matthew P. Goetz, Matthew R. Callstrom, J. William Charboneau et al. · Journal of Clinical Oncology · 2004 · 607 citations · Full text

Medicine, Oncology, Surgery +17

Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)

Riccardo Lencioni, Laura Crocetti, Roberto Cioni et al. · The Lancet Oncology · 2008 · 528 citations

Medicine, Oncology, Surgery +7

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore‐Bianchi, Filippo Pietrantonio, Sara Lonardi et al. · Nature Medicine · 2022 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Correlations between diffusion-weighted imaging and breast cancer biomarkers

Laura Martincich, Veronica Deantoni, Ilaria Bertotto et al. · European Radiology · 2012 · 246 citations

Medicine, Oncology, Radiology +14